[DISCLOSURE]
HanALL BioPharma (009420) announced on July 19 that it has won a patent in India for its biobetter to treat local inflammation related to tumor necrosis factor receptor-1 polypeptide.
Applying a unique amino acid replacement method, the treatment has significantly improved resistance against proteinase, and will enter 2nd phase clinical trials in China and 3rd phase in the US next year, said the company.
By Hwang You-mee (
glamazon@heraldcorp.com)